The Medicines and Healthcare products Regulatory Agency (MHRA) has released decisions made in February 2026 concerning investigations into advertisements for licensed medicines, with a focus on weight loss treatments. These decisions address complaints related to websites and services that promoted medicinal treatment options for weight loss, indicating potential breaches of advertising regulations for medicines in the UK. The MHRA has made ten specific decisions following these investigations.

Companies and individuals involved in advertising licensed medicines, particularly those related to weight loss, should review these decisions to understand the MHRA's enforcement stance and ensure compliance with UK advertising standards. While specific penalties are not detailed in this summary, non-compliance with advertising regulations can lead to enforcement actions. Regulated entities are advised to consult the MHRA's 'Blue Guide' for comprehensive guidance on medicines promotion and advertising. Contact details for the Advertising Standards Unit are provided for further inquiries or to report concerns.